Hyper IgE syndrome associated with novel and recurrent STAT3 mutations: Two case reports.


Journal

Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R

Informations de publication

Date de publication:
Feb 2019
Historique:
entrez: 9 2 2019
pubmed: 9 2 2019
medline: 27 2 2019
Statut: ppublish

Résumé

Hyper-IgE syndrome (HIES) is a rare primary immunodeficiency presenting as two forms including autosomal dominant HIES (AD-HIES) and autosomal recessive HIES (AR-HIES), which are mainly caused by mutations in STAT3 and DOCK8, respectively. To date, only about 500 cases have been reported worldwide including 37 cases in China. The spectrum and prevalence of mutations and molecular pathogenesis in HIES remain poorly understood. Here we reported two Chinese children presenting clinical manifestations of HIES. Based on medical history, clinical manifestations, and laboratory findings, a diagnosis of HIES was made for both children. Targeted next-generation sequencing (NGS) identified a novel heterozygous deletion of 15 bp (c.1960_1974del, p.G654_D658del or alternatively c.1966_1980del, and p.G656_D660del), and a recurrent missense mutation (c.1144C>T, p.R382W) in STAT3 in the two patients, respectively. The two patients have been given the successful treatment of skin infections with cefaclor. Both patients have been under follow-up for more than 6 months, with no signs of recurrent infections. Our results extend the spectrum of STAT3 mutations associated with ADHIES and highlight the value of targeted NGS in confirming diagnosis of genetic disorders.

Identifiants

pubmed: 30732127
doi: 10.1097/MD.0000000000014003
pii: 00005792-201902080-00008
pmc: PMC6380800
doi:

Substances chimiques

Anti-Bacterial Agents 0
DOCK8 protein, human 0
Guanine Nucleotide Exchange Factors 0
STAT3 Transcription Factor 0
STAT3 protein, human 0
Cefaclor 69K7K19H4L

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e14003

Références

Nature. 1998 Jul 9;394(6689):145-51
pubmed: 9671298
J Clin Immunol. 2017 Feb;37(2):166-179
pubmed: 28197791
J Allergy Clin Immunol. 2009 Dec;124(6):1289-302.e4
pubmed: 20004785
Medicine (Baltimore). 2012 Jul;91(4):e1-e19
pubmed: 22751495
N Engl J Med. 2007 Oct 18;357(16):1608-19
pubmed: 17881745
Medicine (Baltimore). 2018 Apr;97(14):e0215
pubmed: 29620631
N Engl J Med. 1999 Mar 4;340(9):692-702
pubmed: 10053178
Immunity. 2006 Nov;25(5):745-55
pubmed: 17088085
J Allergy Clin Immunol. 2014 May;133(5):1400-9, 1409.e1-5
pubmed: 24589341
Clin Genet. 2016 Feb;89(2):217-21
pubmed: 26293184
Blood. 2016 Dec 29;128(26):3061-3072
pubmed: 27799162
J Allergy Clin Immunol. 2008 Jul;122(1):181-7
pubmed: 18602572
J Allergy Clin Immunol. 2010 Feb;125(2):424-432.e8
pubmed: 20159255
Nature. 2007 Aug 30;448(7157):1058-62
pubmed: 17676033

Auteurs

Ying Deng (Y)

National Office for Maternal and Child Health Surveillance of China, Department of Pediatrics, West China Second University Hospital.
Laboratory of Molecular Epidemiology for Birth Defects, West China Institute of Women and Children's Health, Sichuan University.
Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education.

Tong Li (T)

Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu.

Xiaoqin Xie (X)

Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu.

Dengmei Xia (D)

Department of Dermatology, Southwest Medical University Affiliated Hospital, Luzhou, Sichuan, China.

Li Ding (L)

Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu.

Hongmei Xiang (H)

Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu.

Jessie J Ma (JJ)

Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu.

Wei Li (W)

Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH